Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 4
1991 6
1992 11
1993 15
1994 15
1995 23
1996 10
1997 20
1998 24
1999 16
2000 9
2001 6
2002 14
2003 12
2004 15
2005 17
2006 18
2007 22
2008 19
2009 21
2010 23
2011 16
2012 25
2013 30
2014 31
2015 27
2016 29
2017 26
2018 24
2019 29
2020 24
2021 21
2022 23
2023 27
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

610 results

Results by year

Filters applied: . Clear all
Page 1
Molecular markers in ALL: Clinical implications.
Kimura S, Mullighan CG. Kimura S, et al. Best Pract Res Clin Haematol. 2020 Sep;33(3):101193. doi: 10.1016/j.beha.2020.101193. Epub 2020 Jun 7. Best Pract Res Clin Haematol. 2020. PMID: 33038982 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a main cause of death in children despite recent improvements in cure rates. ...
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a main cause of death in children despite recent i …
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA, Auvil JG, Gerhard DS, Relling MV, Winick NJ, Carroll AJ, Heerema NA, Raetz E, Devidas M, Willman CL, Harvey RC, Carroll WL, Dunsmore KP, Winter SS, Wood BL, Sorrentino BP, Downing JR, Loh ML, Hunger SP, Zhang J, Mullighan CG. Liu Y, et al. Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3. Nat Genet. 2017. PMID: 28671688 Free PMC article.
For example, NRAS/FLT3 mutations were associated with immature T-ALL, JAK3/STAT5B mutations in HOXA1 deregulated ALL, PTPN2 mutations in TLX1 deregulated T-ALL, and PIK3R1/PTEN mutations in TAL1 deregulated ALL, which suggests that different signaling pathways have distinc …
For example, NRAS/FLT3 mutations were associated with immature T-ALL, JAK3/STAT5B mutations in HOXA1 deregulated ALL, PTPN2 mutations in TLX …
Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing.
Li K, Liu Y, Cao H, Zhang Y, Gu Z, Liu X, Yu A, Kaphle P, Dickerson KE, Ni M, Xu J. Li K, et al. Nat Commun. 2020 Jan 24;11(1):485. doi: 10.1038/s41467-020-14362-5. Nat Commun. 2020. PMID: 31980609 Free PMC article.
Comparing with existing methods, the improved systems display more robust perturbations of enhancer activity and gene transcription with minimal off-targets. Allele-specific targeting of enCRISPRa to oncogenic TAL1 super-enhancer modulates TAL1 expression and can …
Comparing with existing methods, the improved systems display more robust perturbations of enhancer activity and gene transcription with min …
TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
Smith C, Goyal A, Weichenhan D, Allemand E, Mayakonda A, Toprak U, Riedel A, Balducci E, Manojkumar M, Pejkovska A, Mücke O, Sollier E, Bakr A, Breuer K, Lutsik P, Hermine O, Spicuglia S, Asnafi V, Plass C, Touzart A. Smith C, et al. Haematologica. 2023 May 1;108(5):1259-1271. doi: 10.3324/haematol.2022.281583. Haematologica. 2023. PMID: 36632736 Free PMC article.
This observation laid the groundwork for an innovative paradigm concerning the activation of proto-oncogenes via genomic alterations of non-coding intergenic regions. However, for the majority of T-ALL expressing TAL1 (TAL1+), the deregulation mechanism remains 'unr …
This observation laid the groundwork for an innovative paradigm concerning the activation of proto-oncogenes via genomic alterations of non- …
Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth.
Sharma A, Mistriel-Zerbib S, Najar RA, Engal E, Bentata M, Taqatqa N, Dahan S, Cohen K, Jaffe-Herman S, Geminder O, Baker M, Nevo Y, Plaschkes I, Kay G, Drier Y, Berger M, Salton M. Sharma A, et al. PLoS Biol. 2023 Jun 28;21(6):e3002175. doi: 10.1371/journal.pbio.3002175. eCollection 2023 Jun. PLoS Biol. 2023. PMID: 37379322 Free PMC article.
Furthermore, our results indicate that TAL1-short binds more strongly to TAL1 E-protein partners and functions as a stronger transcription factor than TAL1-long. ...While TAL1 and its partners are considered promising therapeutic targets in the treatme …
Furthermore, our results indicate that TAL1-short binds more strongly to TAL1 E-protein partners and functions as a stronger t …
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL, Ren X, Chan ZE, Yu M, Makheja M, Rayan NA, Lim MGL, Cheung AMS, Bari S, Chng WJ, Than H, Ouyang J, Rackham O, Tan TZ, Hwang WYK, Chuah C, Prabhakar S, Ong ST. Krishnan V, et al. Blood. 2023 Jun 1;141(22):2738-2755. doi: 10.1182/blood.2022017295. Blood. 2023. PMID: 36857629 Free article.
Employing machine-learning, we identified leukemic stem cell (LSC) and natural killer (NK) cell gene expression profiles predicting imatinib response with >80% accuracy, including no false positives for predicting BC. A canonical erythroid-specifying (TAL1/KLF1/GATA1) r …
Employing machine-learning, we identified leukemic stem cell (LSC) and natural killer (NK) cell gene expression profiles predicting imatinib …
Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis.
Jiang J, Wang J, Yue M, Cai X, Wang T, Wu C, Su H, Wang Y, Han M, Zhang Y, Zhu X, Jiang P, Li P, Sun Y, Xiao W, Feng H, Qing G, Liu H. Jiang J, et al. Cancer Cell. 2020 Feb 10;37(2):200-215.e5. doi: 10.1016/j.ccell.2020.01.001. Cancer Cell. 2020. PMID: 32049046 Free PMC article.
Stabilized MYC, in concert with T cell acute lymphoblastic leukemia 1 (TAL1), directly activates AURKB transcription, constituting a positive feedforward loop that reinforces MYC-regulated oncogenic programs. ...
Stabilized MYC, in concert with T cell acute lymphoblastic leukemia 1 (TAL1), directly activates AURKB transcription, constituting a …
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V. Smith C, et al. Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x. Mol Cancer. 2023. PMID: 36650499 Free PMC article.
The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes possess several dysregulation mechanisms, yet how each mechanism impacts clinical outcome is unclear. Using T-cell acute lymphoblastic leukemia …
The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes pos …
TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Tan SH, Tan TK, Yokomori R, Liao M, Huang XZ, Yeoh AEJ, Sanda T. Tan SH, et al. Leukemia. 2023 Oct;37(10):1969-1981. doi: 10.1038/s41375-023-01993-y. Epub 2023 Aug 17. Leukemia. 2023. PMID: 37591943
In this study, we first identify an evolutionarily conserved enhancer element controlling the MYCN oncogene (named enhMYCN) that is aberrantly activated by the TAL1 complex in T-ALL cells. TAL1-positive T-ALL cells are highly dependent on MYCN expression for their m …
In this study, we first identify an evolutionarily conserved enhancer element controlling the MYCN oncogene (named enhMYCN) that is aberrant …
HPV E7 affects the function of cervical cancer cells via the TAL1/lnc-EBIC/KLHDC7B axis.
Wang J, Xiang F, Liu X, Ma X, Cai X, Yang Y, Shen X, Yuan C, Xiang Y, Xiao H. Wang J, et al. Oncol Rep. 2021 May;45(5):51. doi: 10.3892/or.2021.8002. Epub 2021 Mar 24. Oncol Rep. 2021. PMID: 33760214
High-risk human papillomavirus (HPV)16 and 18 are the primary cause of cervical cancer (CC) and long non-coding RNAs (lncRNAs/lncs) are often abnormally expressed in patients with CC. The authors' previous study indicated that oncogenic enhancer of zeste homolog 2 (EZH2)-b …
High-risk human papillomavirus (HPV)16 and 18 are the primary cause of cervical cancer (CC) and long non-coding RNAs (lncRNAs/lncs) a …
610 results